H ereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited autosomal disease presumed to comprise at least 5-8% of all colorectal cancer (CRC) cases. 1 HNPCC is characterised by the early onset of colon tumours mostly located proximal to the splenic flexure and extracolonic tumours. HNPCC families segregate germline mutations in one of the several DNA mismatch repair genes, such as MSH2, MLH1, PMS1, PMS2, and MSH6. 2 The MSH2 protein is a homologue of the bacterial mutS that recognises mismatched base pairs, and the MLH1 protein is a homologue of the bacterial mutL that interacts with mutS to recruit proteins required for DNA mismatch repair. 2 3 Disruption of the mismatch repair system results in genomic instability in the microsatellite repeats, that is, microsatellite instability (MSI).
Detection of germline mutations in the mismatch repair genes confirms the diagnosis genetically for HNPCC kindreds who are at risk for developing CRCs and extracolonic tumours of the endometrium, small intestine, hepatobiliary tract, kidney, and ovary. 1 4 Mutations of the mismatch repair genes such as MSH2 or MLH1 have so far been reported at most in 45-86% of the HNPCC kindreds fulfilling the Amsterdam criteria. 1 The presence of mutation negative cases raised the question that they harboured mutations in other genes responsible for HNPCC or that mutations are missing simply because of technical failure. PCR based approaches, such as exon by exon genomic DNA amplification, would be unsuitable to detect relatively large genomic alterations such as deletions or rearrangements. On the other hand, RNA based analysis for screening germline mutations was suggested to be disadvantageous owing to the appearance of normal splicing variants [5] [6] [7] and nonsense mediated mRNA decay (NMD), which resulted in the reduction of mRNA from the mutated allele carrying deleterious mutations. 8 Previously, we have reported the application of reverse transcriptase (RT)-PCR/ direct sequencing from RNA samples extracted after puromycin treatment. The translation inhibitor puromycin suppresses NMD caused by nonsense and other deleterious mutations of MLH1. 9 10 This method is simple and efficient for screening MLH1 abnormalities such as nonsense mutations, frameshift mutations, and splicing variants. We report here three cases of novel MLH1 genomic disorganisation, two genomic deletions and one partial duplication, screened by the appearance of the splicing variant, which was enhanced and easily detectable by RT-PCR from puromycin treated samples.
MATERIALS AND METHODS
Patients and eligibility criteria RT-PCR analysis was performed in patients referred to the genetic counselling clinics at the National Cancer Centre Hospital (Tokyo) or Tochigi Cancer Centre Hospital (Utsunomiya, Tochigi). A total of 28 cases were analysed for germline mutations of MSH2 or MLH1 in this study and we focused on three cases that showed large genomic disorganisations of MLH1. All of these cases fulfilled either the Amsterdam criteria II 11 or the modified Amsterdam criteria. [12] [13] [14] The Amsterdam criteria II are as follows: (1) there should be at least three relatives with an HNPCC associated cancer (CRC, cancer of the endometrium, small bowel, ureter, or renal pelvis); (2) one of them should be a first degree relative of the other two; (3) at least two successive generations should be affected; (4) at least
• RNA was extracted from blood samples after treatment using a translation inhibitor, puromycin, to suppress nonsense mediated mRNA decay. The entire coding region of the MLH1 gene was amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and amplified DNA fragments were subjected to direct sequencing.
• When exon(s) skipping was detected, regardless of the absence of mutations in the corresponding exons or their exon-intron junctions, long distance PCR (LD-PCR) was carried out to amplify relatively large genomic regions and analysed by direct sequencing.
• In the analysis of 28 HNPCC kindreds, seven pathogenic mutations of MLH1 were detected, of which three cases showed large genomic disorganisation, including two genomic deletions and one partial duplication. One of the two deletions was a homologous Alu mediated recombination missing 1222 bp and another was a non-homologous L1 mediated recombination missing 6998 bp with insertion of a guanine residue at the breakpoint. The duplication was considered to be a result of Alu mediated homologous recombination encompassing 20.2 kb from intron 2 to intron 10.
• This study showed that the RT-PCR approach on puromycin treated samples focusing on detection of exon(s) skipping was shown to be a sensitive method to screen large genomic alterations of the MLH1 gene.
one should be diagnosed before the age of 50; (5) familial adenomatous polyposis should be excluded in the CRC case(s) if any. The Amsterdam criteria II became adaptable for HNPCC associated cancers, while the original minimum Amsterdam criteria is indicated only for kindreds with colorectal cancer. In Japan, the proportion of CRC cases fulfilling the minimum Amsterdam criteria has been reported to be as low as 0.2%, mostly because of relatively small numbers of family members. 15 In our series, 12 cases fulfilled the Amsterdam criteria II, of which 10 cases fulfilled the minimum Amsterdam criteria. In the modified Amsterdam criteria, it is required that (1) very small families, which cannot be further expanded, can be considered to have HNPCC with only two CRCs in first degree relatives, CRC must involve at least two generations, and one CRC case must be diagnosed at <55 years; (2) in families with two first degree relatives affected by CRC, the presence of a third relative with an unusually early onset neoplasm or endometrial cancer is sufficient. Sixteen cases were eligible for the modified Amsterdam criteria and entered into the study.
Blood samples and RNA based analysis Samples of 20 ml of heparinised peripheral blood lymphocytes (PBL) were obtained from the HNPCC kindreds, who provided informed consent for the study.
RNA extraction with or without puromycin, cDNA synthesis, RT-PCR, and direct sequencing reaction were performed as described previously. 9 Briefly, fresh blood samples were incubated in the presence of puromycin (Sigma Chemical Co, MO) at a concentration of 0.2 mg/ml and in the absence of puromycin for two to six hours at 37°C. Leucocytes were isolated from peripheral blood using Vacutainer CPT tubes TM (Becton Dickinson, NJ). Total RNA was extracted from the leucocytes using the acid guanidium phenol/chloroform method. 16 Analysis of genomic DNA DNA extraction was performed by proteinase K digestion and phenol/chloroform extraction as described previously. 17 In cases showing exon(s) skipping in RT-PCR, germline mutations were searched for in the exon-intron junctions that were skipped in RT-PCR (data not shown). When no germline mutations were detected, long distance PCR (LD-PCR) was extension at 68°C for three minutes. Yields of the PCR products were ascertained by electrophoresis on 0.8% agarose gels stained with ethidium bromide. Sequencing of LD-PCR products was performed as described previously 13 using appropriate primers for each case.
Sequences of the cases examined were compared with the human draft sequence for chromosome 3 containing the MLH1 genomic region (GenBank, accession number NT_005974). The search for repetitive sequences was performed with RepeatMasker and NCBI BLAST analysis. 
RT-PCR/direct sequencing
In RT-PCR/direct sequencing approaches, we found three cases showing abnormal exon(s) skipping of MLH1, without mutations in the exon-intron junctions of the corresponding exons (fig 2 A, B, C) . In case A, the sizes of the RT-PCR products were similar between samples treated with puromycin (P) and without puromycin (NP) (fig 2A) , while direct sequencing showed exclusion of exon 5 that was more prominent in P as compared to NP. In case B, gel electrophoresis of the PCR products showed abnormal bands of about 3.1 kb in P and NP, which is larger than the wild type transcript (2.4 kb), and the intensity of the splicing variant was enhanced in P ( fig 2B) . Sequencing analysis showed variant mRNA representing exon 3 downstream of exon 10, and this was also confirmed by sequencing from the reverse direction in which exon 3 was followed by exon 10, but no exon skipping was observed between exons 10 and 11 ( fig 2B) . This aberrant mRNA was more abundant in P as compared to NP. In case C, the profiles of the exon skipping were complex and three abnormally spliced DNA bands, splicing variants (SV) 1, SV2 and SV3, were shown on 6% polyacrylamide gel electrophoresis ( fig 2C) . These bands were excised from the gel, reamplified, and subjected to sequencing. SV1 was shown to skip from exon 11 to 14, while SV2 and SV3 skipped from exon 9 to 14 and from exon 8 to exon 14, respectively.
Long distance PCR (LD-PCR) from genomic DNA
LD-PCR of genomic DNA was performed to amplify the genomic region including the skipped exons. In case A, showing exclusion of exon 5 (fig 2A) , LD-PCR was performed to span genomic regions from introns 3 to 5. The estimated size of the PCR product amplified from a normal allele was 4.4 kb, while a fragment of 3.2 kb was obtained ( fig 3A) . Direct sequencing of the DNA fragment showed a 1222 bp deletion of the genomic region missing intron 4 to intron 5 ( fig 3A) . In case B, direct sequencing of the RT-PCR product showed the appearance of exon 10 downstream of exon 3. From this result, we speculated on the presence of a partial duplication flanking exon 3 to 10 in the region downstream of exon 10 (figs 2B and 3B). To confirm this hypothesis, we performed LD-PCR by designing a forward primer in intron 10 and a reverse primer in exon 3 with which normal genomic DNA could not be amplified. A fragment of 3.5 kb was amplified from genomic DNA, while there was no amplification from a control sample (fig 3B) . Case C represented a complex form of exon skipping ( fig 3C) and we performed LD-PCR using a combination of primer sets designed to amplify genomic regions flanking exons 9-10, 10-11, 11-12, 12-13, 9-11, 10-12, and 11-13, while no differences were detected in comparison with normal genomic DNA (data not shown). Then, we performed LD-PCR spanning 20.1 kb of the genomic region from exons 11 to 14. This showed a fragment of about 13 kb in case C, while no amplification was obtained in normal controls. Primer walking of this DNA fragment showed a genomic deletion of 6998 bp with an insertion of a guanine residue at the breakpoint ( fig 3C) .
Sequencing analyses of the breakpoints
In all cases, amplified DNA fragments by LD-PCR were sequenced for analysis of the breakpoints (fig 4A, B, C) .
In cases showing skipping of exon 5 (figs 2A and 3A), the deletion was 1222 bp of which the 5′ breakpoint was located at 415 bp upstream of exon 5, and the 3′ breakpoint was at 733 bp downstream of exon 5 ( fig 4A) . The breakpoint was located in the Alu element of which the 5′ end was in intron 4 and the 3′ end was in intron 5, joined by a 16 bp homologous sequence in the core sequence of the Alu element ( fig 4A) . In case B (figs 2B and 3B), sequencing analysis showed that the 5′ breakpoint was located 552 bp downstream of exon 10 and was fused at a point 3002 bp upstream of exon 3. A breakpoint was also located between the Alu elements in introns 10 and 2 joined by 44 bp homologous sequence of which the upstream 19 bp contained the core sequence ( fig 4B) . In case C, showing genomic deletion from introns 11 to 13 (figs 2C and 3C), the breakpoint was located 1082 bp 5′ of exon 12 and 2621 bp 3′ of exon 13, which caused a deletion of 6998 bp including exons 12 and 13. The 5′ end of the breakpoint was located in the LINE1 (L1) element in intron 11, with a guanine (G) residue inserted at the fusion point and followed by a non-repetitive sequence in intron 13 (fig 4C) .
DISCUSSION
Conventional methods for screening MLH1 gene abnormalities are based on exon by exon amplification of the genomic DNA, and such methods are unsuitable for detecting large genomic disorganisation such as large deletions involving whole exons. In this regard, RNA based analyses appeared advantageous, but such methods have a risk of the appearance of normal splicing variants 5 or overlooking deleterious mutations causing NMD. 8 18 Some investigators concluded that the use of whole blood RNA for screening germline mutations in HNPCC kindreds would be problematical. 7 In this study, we analysed MLH1 and MSH2 by RT-PCR/direct sequencing from RNA samples extracted from PBLs treated with puromycin. The appearance of a few normal splicing isomers was eliminated by use of sequencing primers designed to anneal the neighbouring exons, thus excluding the influence of normal splicing isomers. 9 These analyses allowed us to find deleterious mutations carrying nonsense codons or frameshift changes that are likely to cause NMD and are barely detectable by ordinary RT-PCR approaches. Splicing variants were usually caused by mutations in the exon-intron boundaries or the appearance of a nonsense codon in the skipped exon 19 ; however, responsible mutations were not necessarily detected. In this study, we detected three large structural abnormalities of the MLH1 gene in three unrelated families. Cases A and B fulfilled the Amsterdam criteria II, while case C was considered to be a variant form in that the proband suffered from three multiple primary cancers, two colon and one ovarian cancers, but there were only two CRCs in the first degree relatives and both parents died of stomach cancer.
In cases A and C, two types of genomic deletion were identified, deletion of 1222 bp and 6998 bp, respectively. In case A, aberrant transcript was identified by direct sequencing, but not by agarose gel electrophoresis of RT-PCR product, in that molecular weights of normal and aberrant transcripts were similar. In case B, a partial duplication between introns 3 and 10 was detected, the size of which reached approximately 20.2 kb in the genomic region. To our knowledge, this is the first report of genomic duplication in MLH1.
In cases A and B, exon skipping was obscured in the sequencing profiles of the samples not treated with puromycin (fig 2A, B) . Particularly in case A, exon skipping was barely detectable by agarose gel electrophoresis and direct sequencing from the sample without puromycin treatment, elucidating the usefulness of puromycin treatment in detecting deleterious mutations.
In cases A and B, no mutations were detected in the corresponding exons or their splice sites, and we suspected that they were caused by large genomic alterations. LD-PCR and subsequent primer walking were carried out to search for the breakpoints. In case A, the breakpoint was located in the left arm of the last Alu element in intron 4 and that of the first Alu element in intron 5, joined by a 16 bp homologous sequence (figs 3A and 4A). In case B, the breakpoint was located in the right arm of the first Alu element in intron 10 and in intron 2 with 44 bp homologous sequences of which the upstream 16 bp belonged to part of the core sequence ( fig 4B) . Alu mediated homologous recombinations resulted in one large genomic deletion and one partial duplication in these HNPCC kindreds.
In case C, we characterised the large genomic deletions as big as 6998 bp. The 5′ end of the breakpoint was located in the L1 repetitive element in intron 11 and fused 8633 bp upstream of the exon 14 with the insertion of a guanine residue. There were no significant homologies between corresponding normal 5′ and 3′ regions flanking the breakpoint, so non-homologous recombination was a likely mechanism for this deletion. In case C, three types of alternatively spliced bands were detected on RT-PCR analysis ( fig 2C) . Two of them (SV1 and SV3) showed enhanced intensities in the puromycin treated sample (P), while the second band (SV2) was strong in the sample not treated with puromycin (NP). The pattern of exon skipping in each transcript was different, that is, exons 12 to 13 were excluded in SV1, 10 to 13 in SV2, and 9 to 13 in SV3, respectively. The lengths of the missing exons were 520 bp in SV1 and 881 bp in SV3, while it was 768 bp in SV2. The differences in signal intensities of these aberrant transcripts with or without puromycin treatment might be the result of the presence or absence of NMD. Skipping of exons 12 to 13 and 9 to 13 resulted in out of frame mutations where nonsense codons appeared 42 bp downstream of exon 14 in SV1 and 19 bp downstream of exon 8 in SV3, respectively. On the other hand, skipping of exons 10 to 13 resulted in an in frame deletion yielding a product missing 256 amino acids in the protein sequence and escaped NMD. These results indicated the effect of puromycin treatment in suppressing NMD and its usefulness for detecting deleterious mutation.
In considerable numbers of HNPCC families, genetic diagnosis is still difficult and approximately 40-50% of the kindreds fulfilling the criteria showed negative results. Large genomic disorganisation may account for these negative results in part. Searching the ICG-HNPCC mutation database (http://www.nfdht.nl/database/mdbchoice.htm, last update in August 2002), a total of 448 germline mutations of MSH2 and MLH1 have been reported so far (291 for MLH1 and 157 for MSH2) and genomic deletion was found in only 16 cases (3.5%) (eight cases for MLH1 and eight cases for MSH2, respectively). Recently, large genomic deletions of the MSH2 gene were detected in analysis of the rat heterohybridoma carrying human haploid chromosome from HNPCC kindreds in whom no relevant mutations were detected by the conventional analyses. 20 There were no reports as to the gene duplication of MLH1 and this study is the first one showing such genomic alterations in the MLH1 gene. Recently, multiplex PCR approaches were introduced in assessing the gene dosage of each exon in either MSH2 or MLH1. 21 22 This is a useful approach for screening genomic alterations of these genes; however, they did not provide the information for the resulting transcript. As shown in case C, our analysis elucidated that genomic deletion from introns 11 to 13 resulted in three types of splicing variants ( fig 2C) and these changes might have implications for understanding the phenotypic manifestation of the case. In our series, a total of 28 kindreds fulfilled either the Amsterdam criteria II or the modified Amsterdam criteria, and pathogenic mutations of either MLH1 or MSH2 were detected in seven and three cases, respectively. Of these, large genomic disorganisation was found in three cases (10.7%), all of which were found only in MLH1, including two large genomic deletions mediated by Alu or L1 elements and one Alu mediated partial duplication. The frequency of large genomic disorganisation in MLH1 reached 43% (3/7) in this study, suggesting that large genomic disorganisation of MLH1 might be a more frequent genetic event. We also indicated that screening for MLH1 germline mutation by RT-PCR/direct sequencing from puromycin treated samples and subsequent analysis using LD-PCR was an efficient diagnostic method for screening for large genomic disorganisations. This approach may also be applicable for diagnosis of other hereditary disorders showing negative results by conventional DNA based screening methods.
